找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Dyslipidemias; Pathophysiology, Eva Abhimanyu Garg Book 2015 Humana Press 2015 Abetalipoproteinemia.Chronic kidney disease.Drug-induced dys

[復(fù)制鏈接]
查看: 8029|回復(fù): 63
樓主
發(fā)表于 2025-3-21 16:24:27 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Dyslipidemias
副標(biāo)題Pathophysiology, Eva
編輯Abhimanyu Garg
視頻videohttp://file.papertrans.cn/285/284374/284374.mp4
概述State-of-the-art, comprehensive title.Broad, up-to-date overview coupled with detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.Covers full range
叢書名稱Contemporary Endocrinology
圖書封面Titlebook: Dyslipidemias; Pathophysiology, Eva Abhimanyu Garg Book 2015 Humana Press 2015 Abetalipoproteinemia.Chronic kidney disease.Drug-induced dys
描述.Dyslipidemias: Pathophysiology, Evaluation and Management. provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewe
出版日期Book 2015
關(guān)鍵詞Abetalipoproteinemia; Chronic kidney disease; Drug-induced dyslipidemia; Dyslipidemia; Familial lipodyst
版次1
doihttps://doi.org/10.1007/978-1-60761-424-1
isbn_softcover978-1-4939-5852-8
isbn_ebook978-1-60761-424-1Series ISSN 2523-3785 Series E-ISSN 2523-3793
issn_series 2523-3785
copyrightHumana Press 2015
The information of publication is updating

書目名稱Dyslipidemias影響因子(影響力)




書目名稱Dyslipidemias影響因子(影響力)學(xué)科排名




書目名稱Dyslipidemias網(wǎng)絡(luò)公開度




書目名稱Dyslipidemias網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Dyslipidemias被引頻次




書目名稱Dyslipidemias被引頻次學(xué)科排名




書目名稱Dyslipidemias年度引用




書目名稱Dyslipidemias年度引用學(xué)科排名




書目名稱Dyslipidemias讀者反饋




書目名稱Dyslipidemias讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:37:38 | 只看該作者
Interpreter und Arbeitsbereiche,sity lipoproteins (HDL) mediate the transport of cholesterol from the periphery back to the liver for excretion. Normal lipoprotein metabolism is essential for health, and a variety of inherited and acquired disorders disrupt normal lipoprotein metabolism and cause dyslipidemia and other consequence
板凳
發(fā)表于 2025-3-22 00:56:09 | 只看該作者
https://doi.org/10.1007/978-1-84800-310-1 To date, there is only limited experience from Lp(a)-reducing therapy, and apart from nicotinic acid, Lp(a) levels are not impacted by conventional lipid-lowering therapy. Recent studies using novel therapeutic approaches show promise, as apoB antisense inhibitors and proprotein convertase subtilis
地板
發(fā)表于 2025-3-22 08:26:24 | 只看該作者
Abdul Ghafur Hamid,Khin Maung Seinmia of T1D may evolve to be more consistent with that of peripheral hyperinsulinemia and relative euglycemia. Lipid and lipoprotein-related health with its effects on microvascular and macrovascular disease will continue to be an important aspect of health care in people with T1D.
5#
發(fā)表于 2025-3-22 10:00:45 | 只看該作者
6#
發(fā)表于 2025-3-22 15:51:16 | 只看該作者
7#
發(fā)表于 2025-3-22 18:17:25 | 只看該作者
8#
發(fā)表于 2025-3-22 22:11:19 | 只看該作者
9#
發(fā)表于 2025-3-23 02:24:57 | 只看該作者
10#
發(fā)表于 2025-3-23 05:36:39 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 20:12
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
东宁县| 木兰县| 新乐市| 吉木萨尔县| 肇庆市| 漳州市| 襄汾县| 盐亭县| 大渡口区| 绥滨县| 白水县| 洞口县| 嘉鱼县| 壶关县| 宁陵县| 临漳县| 黑龙江省| 阿勒泰市| 祁门县| 桐梓县| 阜新市| 新化县| 竹北市| 双鸭山市| 连平县| 景泰县| 宝山区| 醴陵市| 新河县| 普陀区| 宝山区| 荥阳市| 夹江县| 延川县| 温宿县| 吐鲁番市| 信丰县| 宾阳县| 奉化市| 东至县| 资源县|